Home › Funds › Bellevue Group AG › CRNX
Bellevue Group AG position in CRNX
CRINETICS PHARMACEUTICALS IN
Bellevue Group AG reported holding 2,620,000 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$98.0M, representing 2.06% of its reported portfolio and ranking #16 among its reported holdings. Bellevue Group AG has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's CRNX position evolved
Bellevue Group AG first disclosed a stake in CRNX in Q4 2025 at 4,040 shares (US$188K). The position peaked in Q1 2026 at 3,280,000 shares, worth US$119.1M. Across 3 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,620,000 shares valued at US$98.0M — a reduction of -660,000 shares quarter over quarter.. Notable position changes include a 81088% increase in Q1 2026.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 4.04K | $188.06K | New |
| Q1 2026 | 3.28M | $119.13M | Add |
| Q2 2026 | 2.62M | $98.04M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRNX and 13F data
CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRNX
- Farallon Capital Management 8.99M sh · $336.37M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 8.99M sh · $336.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.46M sh · $241.87M · Q2 2026
- BAKER BROS. ADVISORS LP 2.35M sh · $87.99M · Q2 2026
- Siren, L.L.C. 1.42M sh · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M sh · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M sh · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M sh · $44.39M · Q2 2026
- ORBIMED ADVISORS LLC 999.00K sh · $37.38M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held CRNX?
Bellevue Group AG has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Bellevue Group AG's current position in CRNX?
As of Q2 2026, Bellevue Group AG holds 2.62M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $98.04M, representing 2.06% of its reported portfolio and ranking #16.
Has Bellevue Group AG been buying or selling CRNX?
In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in CRNX. The position peaked in Q1 2026 at 3.28M shares.
Which other funds hold CRNX?
Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.